Sep 24, 2025
Sapu Nano's Sapu003 Advances to Human Clinical Testing - Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
Sep 18, 2025
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments
Sep 16, 2025
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Building Breakthrough Portfolio Aimed at Transforming Cancer, Rare Disease Treatments
Sep 12, 2025
Oncotelic Therapeutics Highlights 2 Years of Clinical and Regulatory Advancements Across Late-Stage Pipeline
Sep 04, 2025
Dr. Vuong Trieu, Developer of Novel Oncology and Immunotherapy Assets, Leads Oncotelic Therapeutics' Commitment to Innovation, Life-Saving Therapies
Aug 28, 2025
Oncotelic Therapeutics Showcases Robust Pipeline and Founder's Broad Intellectual Property Contributions to Biopharma Industry
Jul 17, 2025
Oncotelic Therapeutics Highlights Peer Reviewed Publication Linking TGFB2 to Survival in Younger Pancreatic Cancer Patients
Jun 25, 2025
Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer
Apr 22, 2025
Oncotelic CEO Vuong Trieu to Present Innovative "Deciparticles" Platform at IDDST-Europe 2025 Conference in Stockholm
Apr 16, 2025
Oncotelic Therapeutics Reports FY 2024 Highlights and FY 2024 Earnings Compared to FY 2023
   1    2   3   4   5   6 
 <<   <   >   >> 
Copyright © 2021 Oncotelic Inc., a TGF ImmunoOncology Company. All rights reserved.